Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 3, 290(21), 2805-2816. [PMID]: 14657064.

Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-Dehoff R, Pepine CJ. Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. Hypertension. 2004 Nov, 44(5), 637-642. [PMID]: 15381674.

Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ; INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J. 2008 Aug, 156(2), 241-247. [PMID]: 18657652 .